Professor Michael Zelefsky
is a recognized international authority in the treatment of prostate cancer with radiotherapy. He is currently Vice Chair of the Department of Radiation Oncology and Chief of the Brachytherapy Service at Memorial Sloan Kettering Cancer Center. He also serves as a leader of the Genito-urinary Disease Management Team at Memorial Sloan Kettering and has been instrumental in the development of novel radiation techniques that have been adopted worldwide, including IMRT, IGRT, and intraoperative adaptive brachytherapy treatment planning. Professor Zelefsky has published more than 300 publications as well as chapters and textbooks. He is currently exploring approaches using targeted biologic agents concurrently with hypofractionated stereotactic radiosurgery for high-risk disease as well as the implementation of novel brachytherapy techniques to improve the precision of brachytherapy in the treatment of prostate cancers. Dr. Zelefsky is the Editor inChief of
Brachytherapy
, the premier journal in the world for articles devoted to the use of brachytherapy in the treatment of cancer.

Offers a comprehensive evaluation of the use of stereotactic body radiosurgery for treatment of prostate cancer

Provides clear guidance on safe treatment delivery that will aid both students of radiation oncology and more experienced practitioners

Summarizes expected and reported treatment outcomes with the aid of an abundance of tables and figures

Chapter 1: Optimizing Selection of Patients for Prostate SBRT (Kishan, A., King, C.).- Chapter 2: Treatment Planning Considerations for Prostate SBRT and MRI Based Planning (Tyagi, N., Hunt, M.).- Chapter 3: Organ Motion Considerations and Tracking During Prostate SBRT (Happersett, L., Lovelock, M.).- Chapter 4: Imaging and Anatomic Considerations for Prostate and Normal Tissue Contouring (Charas, T., Vargas, A.).- Chapter 5: Using Imaging to Design Dose Volume Constraints for Target and Normal Tissue To Reduce Toxicity (Alongi, F., Mazzola, R.).- Chapter 6: Expected PSA and Biochemical Control with Prostate SBRT Compared to Conventional Fractionated Radiotherapy (Kang, J., Katz, A.).- Chapter 7: Overview of Tumor Control Outcomes with Prostate SBRT for Low and Intermediate Risk Prostate Cancer and Comparison to other Treatment Interventions (Taggar, A., Zelefsky, M.).- Chapter 8: Overview of Toxicity Outcomes with Prostate SBRT and Comparison to other Treatment Interventions( Urinary, Rectal and Sexual Outcomes) (Repka, M., Suy, S., Kataria, S., Kole, T., Paydar, I., Collins, B., Lischalk, J., Obayomi-Davies, O., Collins, S.).- Chapter 9: Quality of Life Outcomes after SBRT (Zilli, T., Miralbell, R.).- Chapter 10: Techniques for Reducing Toxicity after SBRT (Kollmeier, M., Zelefsky, M., Gorovets, D.).- Chapter 11: SBRT for High Risk Prostate Cancer (González-Motta, A., Anwar, M., Gottschalk, A., Descovich, M., Roach III, M.).- Chapter 12: Salvage SBRT for Recurrence after Definitive Radiotherapy (Hannoun-Lévi, J., Doyen, J., Falk, A., Lamchamkee, D.).- Chapter 13: Dose Escalation for Prostate SBRT (Folkert, M., Robert, T.).- Chapter 14: Summary of Ongoing Prospective Trials using SBRT for Prostate Cancer (van As, N., Morrison, K.).- Chapter 15: Concluding Remarks and Overall Perspectives (Zelefsky, M.).